Episode 466 (March 5, 2026) opens with breaking legal and policy news: the Trump EPA has filed a brief at the U.S. Supreme Court backing Bayer/Monsanto and glyphosate (Roundup). Del breaks down what the government is arguing, what's at stake for warning labels and litigation, and why the outcome could reshape corporate accountability around glyphosate-based herbicides.

Then, Jefferey Jaxen covers the accelerating shift in public vaccine sentiment, as global vaccine uptake declines and pharmaceutical stocks react to falling demand. Del analyzes the latest reported data, including a major worldwide drop in Gardasil (HPV vaccine) uptake, and what these trends could signal for vaccine policy, mandates, and the future of the vaccine marketplace.

Also, a dive into the growing national debate over vaccine manufacturer liability. New polling indicates strong public support for restoring legal accountability for vaccine makers, a key issue tied to vaccine injury protections, medical freedom, and federal vaccine policy.

Plus, an in-studio scientific discussion you don't want to miss: Del is joined by Dr. James Neuenschwander and Dr. Brian Hooker to break down a new study examining aluminum in vaccines and the potential implications for vaccine safety research, adverse event risk, and the broader childhood vaccination schedule.